Overview

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Di

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

Phase:

Phase 1

Details

Lead Sponsor:

Sunovion Respiratory Development Inc.

Treatments:

Bromides
Charcoal
Glycopyrrolate